Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Penile Neoplasms | 4 | 2019 | 32 | 0.650 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2016 | 18 | 0.550 |
Why?
|
| Noise | 1 | 2016 | 19 | 0.540 |
Why?
|
| Verbal Behavior | 1 | 2016 | 52 | 0.540 |
Why?
|
| Operating Rooms | 1 | 2016 | 69 | 0.530 |
Why?
|
| Lymph Node Excision | 3 | 2019 | 157 | 0.460 |
Why?
|
| Communication | 1 | 2016 | 507 | 0.400 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2019 | 641 | 0.340 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 396 | 0.330 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2022 | 542 | 0.280 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 190 | 0.180 |
Why?
|
| Urologic Neoplasms | 1 | 2019 | 39 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2021 | 364 | 0.150 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 58 | 0.150 |
Why?
|
| Calculi | 1 | 2017 | 15 | 0.140 |
Why?
|
| Lithotripsy, Laser | 1 | 2017 | 12 | 0.140 |
Why?
|
| Kidney Calculi | 1 | 2017 | 40 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2019 | 377 | 0.140 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 125 | 0.140 |
Why?
|
| Music | 1 | 2016 | 15 | 0.140 |
Why?
|
| Endoscopy | 1 | 2018 | 283 | 0.130 |
Why?
|
| Nephrectomy | 1 | 2017 | 173 | 0.130 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 1214 | 0.120 |
Why?
|
| Inguinal Canal | 3 | 2019 | 11 | 0.120 |
Why?
|
| Medical Errors | 1 | 2016 | 155 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2016 | 616 | 0.110 |
Why?
|
| Postoperative Complications | 3 | 2021 | 2999 | 0.100 |
Why?
|
| Patient Safety | 1 | 2016 | 390 | 0.100 |
Why?
|
| Skin Physiological Phenomena | 1 | 2011 | 19 | 0.100 |
Why?
|
| Dermatology | 1 | 2011 | 34 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1518 | 0.090 |
Why?
|
| Cystectomy | 2 | 2022 | 152 | 0.090 |
Why?
|
| Laparoscopy | 1 | 2017 | 502 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2022 | 12033 | 0.090 |
Why?
|
| Physical Examination | 1 | 2011 | 163 | 0.090 |
Why?
|
| Cholecystokinin | 1 | 2009 | 13 | 0.090 |
Why?
|
| Protein Kinase C-delta | 1 | 2009 | 17 | 0.090 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 53 | 0.080 |
Why?
|
| Pancreas | 1 | 2009 | 214 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 321 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 653 | 0.070 |
Why?
|
| Humans | 12 | 2022 | 122517 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2009 | 745 | 0.060 |
Why?
|
| Equipment Design | 2 | 2018 | 598 | 0.060 |
Why?
|
| Male | 8 | 2021 | 59687 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2022 | 77 | 0.050 |
Why?
|
| Muscles | 1 | 2022 | 289 | 0.050 |
Why?
|
| Cisplatin | 1 | 2022 | 254 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2022 | 603 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 145 | 0.040 |
Why?
|
| Quality of Life | 2 | 2020 | 1908 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 4488 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2022 | 15906 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2018 | 7 | 0.040 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 92 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 267 | 0.040 |
Why?
|
| Foot | 1 | 2018 | 61 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 5983 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 99 | 0.040 |
Why?
|
| Niobium | 1 | 2017 | 1 | 0.040 |
Why?
|
| Silicon Dioxide | 1 | 2017 | 27 | 0.040 |
Why?
|
| Lasers, Solid-State | 1 | 2017 | 17 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 751 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 487 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2017 | 152 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2018 | 193 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2018 | 193 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2017 | 122 | 0.030 |
Why?
|
| Operative Time | 1 | 2017 | 160 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 146 | 0.030 |
Why?
|
| Cicatrix | 1 | 2017 | 125 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1229 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1250 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 511 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2019 | 656 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1998 | 0.030 |
Why?
|
| Middle Aged | 3 | 2020 | 25651 | 0.030 |
Why?
|
| Swine | 1 | 2017 | 1158 | 0.030 |
Why?
|
| Sebum | 1 | 2011 | 1 | 0.030 |
Why?
|
| Skin Aging | 1 | 2011 | 14 | 0.020 |
Why?
|
| Skin Pigmentation | 1 | 2011 | 27 | 0.020 |
Why?
|
| Esthetics | 1 | 2011 | 37 | 0.020 |
Why?
|
| Abdomen | 1 | 2011 | 131 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 425 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 1431 | 0.020 |
Why?
|
| Face | 1 | 2011 | 181 | 0.020 |
Why?
|
| Trypsinogen | 1 | 2009 | 1 | 0.020 |
Why?
|
| Maleimides | 1 | 2009 | 12 | 0.020 |
Why?
|
| Acetophenones | 1 | 2009 | 13 | 0.020 |
Why?
|
| Benzopyrans | 1 | 2009 | 19 | 0.020 |
Why?
|
| Amylases | 1 | 2009 | 26 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 4983 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 312 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2009 | 118 | 0.020 |
Why?
|
| Skin | 1 | 2011 | 506 | 0.020 |
Why?
|
| Indoles | 1 | 2009 | 182 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 1239 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 462 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 6186 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 580 | 0.020 |
Why?
|
| Female | 3 | 2021 | 65064 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1214 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4308 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1687 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 9883 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 2788 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2009 | 3075 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3659 | 0.010 |
Why?
|
| Animals | 2 | 2017 | 33911 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 18836 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 3782 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 4391 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 8809 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 18987 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 17646 | 0.010 |
Why?
|
| Adult | 1 | 2011 | 28800 | 0.010 |
Why?
|